These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 19627400)

  • 1. Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70.
    Xie Y; Bai O; Zhang H; Yuan J; Zong S; Chibbar R; Slattery K; Qureshi M; Wei Y; Deng Y; Xiang J
    J Cell Mol Med; 2010 Nov; 14(11):2655-66. PubMed ID: 19627400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
    Xie Y; Bai O; Zhang H; Li W; Xiang J
    Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity.
    Hao S; Bai O; Li F; Yuan J; Laferte S; Xiang J
    Immunology; 2007 Jan; 120(1):90-102. PubMed ID: 17073943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
    Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
    Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells.
    Liu Y; Qureshi M; Xiang J
    Cancer Biother Radiopharm; 2002 Feb; 17(1):11-8. PubMed ID: 11915168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells.
    Chen W; Wang J; Shao C; Liu S; Yu Y; Wang Q; Cao X
    Eur J Immunol; 2006 Jun; 36(6):1598-607. PubMed ID: 16708399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fusion hybrid of dendritic cells and engineered tumor cells expressing interleukin-12 induces type 1 immune responses against tumor.
    Shi M; Su L; Hao S; Guo X; Xiang J
    Tumori; 2005; 91(6):531-8. PubMed ID: 16457153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity.
    Zhang H; Xie Y; Li W; Chibbar R; Xiong S; Xiang J
    Cell Mol Immunol; 2011 Jan; 8(1):23-30. PubMed ID: 21200381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
    Xia D; Li F; Xiang J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
    Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity.
    Xie Y; Zhang H; Li W; Deng Y; Munegowda MA; Chibbar R; Qureshi M; Xiang J
    J Immunol; 2010 Nov; 185(9):5268-78. PubMed ID: 20881190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity.
    Liu Y; Zhang W; Chan T; Saxena A; Xiang J
    Leuk Res; 2002 Aug; 26(8):757-63. PubMed ID: 12191571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural CD8⁺25⁺ regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocyte-mediated immunity against B16 melanoma.
    Xie Y; Zhang X; Zhao T; Li W; Xiang J
    Biochem Biophys Res Commun; 2013 Aug; 438(1):152-5. PubMed ID: 23876314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
    Hao S; Bai O; Yuan J; Qureshi M; Xiang J
    Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.
    Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J
    Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70.
    Moroi Y; Mayhew M; Trcka J; Hoe MH; Takechi Y; Hartl FU; Rothman JE; Houghton AN
    Proc Natl Acad Sci U S A; 2000 Mar; 97(7):3485-90. PubMed ID: 10725409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity.
    Shanker A; Buferne M; Schmitt-Verhulst AM
    Immunology; 2010 Jan; 129(1):41-54. PubMed ID: 20050329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
    Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
    J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
    Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
    Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.